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The prevalence of allergic diseases is rising worldwide 
and certainly in South Africa (SA). Every few weeks 
the major allergy journals list new allergens identified 
as triggering allergic reactions. There have recently 
been significant advances in the diagnosis and 
management of allergic disorders. 
It may be prudent to consider diagnostic and management 
advances for the SA generalist in two ways. There are a host of new 
SA guidelines for the diagnosis and management of all the allergic 
diseases; these might be considered as the ‘practical advances’. There 
are also new diagnostic and therapeutic approaches that may be 
considered as the ‘possible advances’. ‘Possible’, because even though 
these advanced tests and therapies are available they should not be 
utilised without proper cause. 
This article focuses on these two approaches, the latest guideline 
suggestions and some of the new ideas regarding diagnosis in the 
laboratory and therapy in the clinic.
Practical advances
A number of SA ‘guidelines’ have been published in the past year 
and should form the basis of any rational decision-making in the 
diagnosis and management of allergic disorders.
The general approach to the management of atopic dermatitis can 
be presented schematically (Fig. 1).[1]
The SA Allergic Rhinitis Working Group published the require-
ments with regard to the management of chronic rhinitis (CR) 
(Table 1).[2]
The Allergy Society of SA, together with the National Pathology 
Group, revised algorithms for the investigation of allergic patients. 
The algorithm for investigating a suspected allergic patient 
summarises that approach (Fig. 2).[3]
In late 2013 the Allergy Society of SA, in partnership with other 
stakeholders, formulated food allergy guidelines for SA. In those 
guidelines there is a statement on indications for the prescription 
of adrenaline (EpiPen) to patients (Table 2).[4] The same document 
listed the prevalence and prognosis of various food allergies 
(Table 3). These are international figures, whereas SA data are still 
being accumulated.
Possible advances
There have been a number of advances in allergy diagnostics and 
therapy. Two of these are the development of a new diagnostic 
modality, the multiplex microarray chip, and in the therapeutic realm 
new progress in immunotherapy.
There have been a number of advances in the diagnosis and management of allergic diseases that are relevant to South African (SA) 
circumstances. These are all published or about to be published in new guidelines that provide practical advice to guide SA doctors who 
treat patients with these conditions. The guidelines include those for atopic dermatitis, allergic rhinitis and food allergy. This article reflects 
the most pertinent aspects of the guidelines. It also provides a short summary of a new allergy diagnostic test available in SA, the multiplex 
microarray chip, known as the immuno-solid-phase allergen chip (ISAC) test. It provides component-resolved allergy testing for special 
circumstances and complex allergic problems and is certainly not required as a screening allergy test. Finally, this article gives an update on 
allergen immunotherapy – some patients with allergic conditions may benefit from immunotherapy. In SA, some forms of immunotherapy 
for allergic rhinitis and mild asthma may currently include sublingual immunotherapy.
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Table 1. Requirements for the management of chronic rhinitis (CR) in South Africa (SA)
• Consider CR as a multifactorial condition of which allergic rhinitis is but one cause
• Long-term studies of change in prevalence of CR in relation to climate change are needed
• The allergic rhinitis Essential Medicine List[12] for SA should be updated to reflect safe and effective therapy – sedating antihistamine
therapy must not be recommended
• Medical aid organisations must be encouraged to allow CR therapy as a chronic benefit
• Medication should be tailored to individual patients
• Patient education regarding CR is very important
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Immuno-solid-phase allergen chip 
(ISAC) microarray test[5]
The ISAC is a multiplex microarray chip 
test in which immunoglobulin (Ig) E is 
detected to multiple recombinant allergen 
components. The current ISAC microchip 
is a miniaturised immunoassay platform 
using only 20 µl of serum to measure specific 
IgE to 112 different recombinant allergen 
components. It should not be used as a 
screening test in patients with a history of 
a low suspicion of allergy, but should be 
used as a diagnostic tool in patients with 
suspected allergen cross-reactivity such as 
combined food and pollen allergies or in 
patients with multiple allergies.
Clinical value of IgE testing to 
allergen components
One of the major advantages of component 
testing is the ability to distinguish between 
primary, species-specific sensitisation, and 
cross-reactivity to proteins with similar 
protein structures, which may contribute 
towards evaluating the risk of reaction on 
exposure to different allergens. Protein 
structure and stability to heat and digestion 
may affect tolerance to raw or cooked foods 
and the severity of clinical reactions.  This 
information can be used to individualise 
patient management by including advice 
on targeted allergen exposure reduction, 
selection of suitable allergens for specific 
immunotherapy or need to perform food 
challenges.[6-9] 
Pollen allergy and cross-reactive 
food allergy
Patients with pollen allergies are often 
sensitised to cross-reactive components 
that occur in pollens and foods of plant 
origin. The most common ones are cross-
reactive carbohydrate determinants (CCD), 
profilins, proteinase-10 (PR-10) and lipid 
transfer proteins (LTP). Clinical relevance 
and severity of reactions can be predicted, 
e.g. IgE to CCD is the least likely to cause 
symptoms. The likelihood of symptomatic 
allergy increases with IgE to profilin, then 
PR-10 and LTP, the last being the most 
likely to induce clinically relevant reactions. 
Profilin and PR-10 are also heat labile; 
therefore patients with this allergy may be 
able to tolerate cooked food while being 
symptomatic to raw food. Knowledge of 
protein localisation may also contribute to 
patient management, as PR-10 is mainly 
localised to the pulp of fruit and LTP to 
the peel. Patients with LTP allergy may 
sometimes be able to tolerate peeled fruit. 
As cross-reactivity may have a substantial 
impact on patient management, there should 
be a greater awareness when interpreting 
allergy tests regarding potential cross-
reactivity between pollens and food of 
plant origin. A typical pointer to potential 
cross-reactivity is pollens and several foods 
of plant origin that are positive on IgE-
mediated allergy tests, especially positive 
reactions to a combination of wheat, peanut 
and soy.
Milk allergy 
The major allergens are casein (Bos d 8), 
alpha-lactalbumin (Bos d 4) and beta-
lactoglobin (Bos d 5), although allergies 
to minor proteins such as bovine serum 
albumin (BSA) (Bos d 6) and lactoferrin 
(Bos d lactoferrin) have been reported. Casein, 
the most important and abundant allergen in 
milk and hard cheese, is heat stable. Patients 
with high levels of IgE to casein are at risk 
for severe reactions and are less likely to 
outgrow their milk allergy. Note that there is 
a high homology between casein of different 
species, and patients with casein reactivity 
have a high risk of reacting to the milk of 
other animal species. Whey proteins (alpha-
lactalbumin and beta-lactoglobin) are heat 
labile and patients reacting to these proteins 
may often tolerate heated or fermented milk 
products. BSA is a serum albumin that is a 
main protein in mammalian blood and an 
important allergen involved in milk, meat 
and epithelia allergy. Sensitised patients may 
react to different meats (beef, lamb and 
pork), epithelia (cat and dog) and cow’s milk.
Egg allergy
Egg white is the most important source 
of egg allergy and contains 23 different 
proteins. The most important allergens are 
ovomucoid (Gal d 1), ovalbumin (Gal d 2), 
ovotransferrin/conalbumin (Gal d 3) and 
lysozyme (Gal d 4). Although ovomucoid 
comprises only 10% of the total egg 
white protein, it has been shown to be 
the dominant allergen and is allergenic 
in minute amounts. This protein is very 
stable to heat and digestion; therefore, 
allergic patients cannot tolerate egg in 
baked products. High levels of IgE to Gal d 1 
are also associated with persistent egg allergy. 
However, absence or low levels of IgE 
antibodies to Gal d 1 are associated with 
an increased probability of tolerance to 
ingestion of cooked egg. This may guide 
clinicians in when they should perform a 
cooked egg challenge. Gal d 5 is present as 
the protein egg livetin in egg yolk and in 
chicken as chicken serum albumin and may 
cause ‘bird-egg syndrome’, where patients 
Table 2. Self-injectable adrenaline devices and indications for their prescription in the 
community
Absolute indications
Previous anaphylaxis to a food, an insect sting, latex or unavoidable aeroallergen
Food-dependent exercise-induced anaphylaxis
Idiopathic anaphylaxis
Coexistent unstable or moderate to severe, persistent asthma and a food allergy
Relative indications
Mild to moderate peanut and/or tree nut allergy in persons >5 years of age
Food allergy in a teenager or young adult
Great distance to a medical facility
Reactions to small amounts of food, such as air-borne food allergens or contact via skin only
Table 3. Summary of prevalence to individual food allergens[4]
Allergen Prevalence in young children Prognosis
Cow’s milk 0.3 - 3.5% (<0.5% in adults) >80% outgrown by 16 years
Hen’s egg 0.5 - 8% (<0.5% in adults) >80% outgrown by 16 years
Wheat <1% Majority outgrow – 65% by 12 years
Fish <0.2% (children) and <0.5% (adults) Usually allergic for life
Shellfish <0.5% (children) and <2.5% (adults) Usually allergic for life
Peanut 0.06 - 5.9% 20% outgrown
Tree nut 0.2 - 1.4% 10% outgrown
Plant food 0.1 - 4.3%
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may react to egg yolk, chicken meat and 
feathers.
Immunotherapy
Allergen immunotherapy has been used 
to treat allergic diseases, such as asthma, 
allergic rhinitis, and venom allergy for more 
than a century. Subcutaneous immuno-
therapy involves the administration of 
clinically relevant allergens for several 
months, building up to eventual monthly 
injections – typically for 3 - 5 years. 
Recent advances have improved the 
safety and efficacy of immunotherapy. 
The addition of omalizumab or toll-
like receptor agonists to standard 
subcutaneous immunotherapy has proved 
beneficial. Altering the extract itself, 
Diagnosis
Pruritus: ≥3 of the following:
Assess severity
•
•
•
•
•
History of exural dermatitis (front of elbows, back of knees, front of ankles,
neck, around the eyes) or involvement of cheeks and/or extensor surfaces in
children ≥18 months of age 
Visible exural dermatitis involving the skin creases (or the cheeks and/or
extensor surfaces in children ≥18 months of age)
History of a generally dry skin in the past year
Personal history of asthma or hay fever (history of atopic disease in a
rst-degree relative in children <4 years of age)
Onset <2 years of age (used only for children ≥4 years at time of diagnosis)
Remission
Flare
Active disease
Patient education, emollients
Acute control of pruritus and
inammation
•
•
•
Topical corticosteroids (TCSs)
Topical calcineurin inhibitors (TCIs)
Address reason(s) for are with
antibiotics, etc.
Adjunctive therapy
Trigger avoidance
Correct bathing
Skin care
Antibacterials
Antifungals
Antivirals
Psychological interventions
Sedating antihistamines
Maintenance therapy/chronic treatment
At the earliest sign of disease recurrence: TCIs
Long-term TCIs for selected skin areas to prevent ares, or intermittent TCSs weekly to prevent
ares
Intermittent medium-potency TCSs for ares, until subsided
Severe refractory cases, frequent ares, poor response, moderate dermatitis in young patients
Refer to dermatologist/paediatrician/allergist, as appropriate
Potent TCSs
Phototherapy (narrow-band ultraviolet B)
Cyclosporin, methotrexate, oral corticosteroids, azathioprine, mycophenolate mofetil, 
intravenous immunoglobulin, interferon-gamma
Psychotherapeutic intervention
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Fig. 1. Guidelines for the management of atopic dermatitis.
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either through chemical manipulation 
producing allergoids or directly producing 
recombinant proteins or significant 
peptides, has been evaluated – with 
promising results. The use of different 
administration techniques, such as 
sublingual immunotherapy, is common 
in SA. Other methods of administering 
allergen immunotherapy have been studied, 
including epicutaneous, intralymphatic, 
intranasal, and oral immunotherapy.[10] 
For patients with certain allergic profiles, 
immunotherapy may be an important 
treatment modality. Such patients include 
those with bee venom anaphylaxis, allergic 
rhinitis and mild asthma.
New in this arena is that immunotherapy 
no longer requires receiving injections for 
years. For aeroallergen allergy oral and 
sublingual immunotherapy is now available. 
The indications for immunotherapy are 
listed in Table 4.[11]
Conclusion
This article summarises the important facts 
present in SA guidelines, which summarise 
current trends in the management of 
common allergic diseases and have locally 
relevant practice suggestions.
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Table 4. Indications for immunotherapy
• Proven sensitisation to grass pollen or house-dust mite (allergic rhinitis or mild asthma
• Bee or wasp venom anaphylaxis
• Selected patients with animal hypersensitivity (cats, dogs, horses)
• Selected patients monosensitive to Alternaria
Skin prick tests
Fig. 2. Proposed algorithm for investigating a suspected allergic patient.
History
Suspicion of allergy
Screening tests to exclude
allergy
Screen for IgE as well as
non-IgE-mediated allergy.
May screen for IgE-
mediated rst and, if
negative, proceed with
non-IgE-mediated testing
IgE-mediated Non-IgE-mediated
Phadiatop inhalant
Skin-prick tests
Food mix IgE/food
Skin-prick tests
Nasal eosinophils
(rhinitis symptoms)
CAST inhalant mix
CAST food mix
CAST colourants 
If negative, consider other diseases
Correlate with clinical ndings and history
